Favorable effects of a prolonged treatment with melatonin on the level of oxidative damage and neurodegeneration in senescence‐accelerated mice

Abstract:  Senescence‐accelerated mice (SAMP8) and senescence‐accelerated resistant mice (SAMR1) were studied at 5 and 10 months of age, respectively. In the animals, neurodegenerative processes and how they were influenced by melatonin were examined. Melatonin (10 mg/kg) or vehicle (ethanol at 0.066%) treatments were administrated from the age of 1 to 9 months in the drinking water. Differences in the neurodegenerative markers examined were found between the two strains with a more damaged protein, phosphorylated Tau at Ser392, increased neurofibrillary tangles (NT) and higher α‐synuclein expression in SAMP8 versus SAMR1 mice overall, when the mice were 10 months of age. Changes in density of receptors and oxidative stress‐related signaling with age were found in the brains of SAM strains at 10 months as shown by a marked decrease in the level of MT‐1 melatonin receptor and retinoic acid receptor‐related orphan receptor (ROR)‐α1. This diminution was earlier and more pronounced in SAMP8 mice. Likewise, the levels of nuclear factor‐kappa B (NF‐kB) transcriptional factor were higher in SAMP8 mice compared with SAMR1 mice regardless of age confirming the direct role of oxidative stress in the aging process. Treatment with melatonin in SAMP8 and SAMR1 mice reduced the neurodegenerative changes with an increase of ROR‐α1 levels without an apparent influence in the levels of MT‐1 receptor. However, different melatonin effects on NF‐kB signaling were observed suggesting that NF‐kB could trigger inflammatory processes in a different way, being SAM strain‐dependent and associated with age‐related oxidative stress levels. The effectiveness of melatonin in improving age‐related neural impairments is corroborated.

[1]  R. Reiter,et al.  Melatonin as a naturally occurring co‐substrate of quinone reductase‐2, the putative MT3 melatonin membrane receptor: hypothesis and significance , 2007, Journal of pineal research.

[2]  L. Brusco,et al.  Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study , 2007, Journal of pineal research.

[3]  D. Swaab,et al.  Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease , 2007, Neurobiology of Aging.

[4]  M. Pallàs,et al.  Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8 , 2007, Journal of pineal research.

[5]  K. Manda,et al.  AFMK, a melatonin metabolite, attenuates X‐ray‐induced oxidative damage to DNA, proteins and lipids in mice , 2007, Journal of pineal research.

[6]  K. Mohanakumar,et al.  Melatonin protects against rotenone‐induced oxidative stress in a hemiparkinsonian rat model , 2007, Journal of pineal research.

[7]  D. Acuña-Castroviejo,et al.  Chronic melatonin treatment reduces the age‐dependent inflammatory process in senescence‐accelerated mice , 2007, Journal of pineal research.

[8]  M. Mattson,et al.  NF-κB as a therapeutic target in neurodegenerative diseases , 2007 .

[9]  R. Reiter,et al.  One molecule, many derivatives: A never‐ending interaction of melatonin with reactive oxygen and nitrogen species? , 2007, Journal of pineal research.

[10]  S. Pletcher,et al.  Trade‐offs between longevity and pathogen resistance in Drosophila melanogaster are mediated by NFκB signaling , 2006 .

[11]  P. Phansuwan-Pujito,et al.  Melatonin protects against hydrogen peroxide‐induced cell death signaling in SH‐SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl‐2 , 2006, Journal of pineal research.

[12]  D. Acuña-Castroviejo,et al.  Inhibition of neuronal nitric oxide synthase activity by N1‐acetyl‐5‐methoxykynuramine, a brain metabolite of melatonin , 2006, Journal of neurochemistry.

[13]  H. Chung,et al.  The molecular inflammatory process in aging. , 2006, Antioxidants & redox signaling.

[14]  M. Mulero,et al.  Changes in oxidative stress parameters and neurodegeneration markers in the brain of the senescence-accelerated mice SAMP-8 , 2006, Experimental Gerontology.

[15]  O. Alvarez-Garcia,et al.  Oxidative damage in the livers of senescence-accelerated mice: a gender-related response. , 2006, Canadian journal of physiology and pharmacology.

[16]  Josep M. Guerrero,et al.  Inverse correlation between endogenous melatonin levels and oxidative damage in some tissues of SAM P8 mice , 2006, Journal of pineal research.

[17]  J. Mallet,et al.  Human retinoic acid receptor‐related orphan receptor α1 overexpression protects neurones against oxidative stress‐induced apoptosis , 2006, Journal of neurochemistry.

[18]  O. Alvarez-Garcia,et al.  Elevated Oxidative Stress in the Brain of Senescence-accelerated Mice at 5 Months of Age , 2006, Biogerontology.

[19]  S. Oikawa,et al.  Proteomic analysis for protein carbonyl as an indicator of oxidative damage in senescence-accelerated mice , 2006, Free radical research.

[20]  E. Stadtman Protein oxidation and aging , 2006, Science.

[21]  M. Pallàs,et al.  Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM) , 2005, Mechanisms of Ageing and Development.

[22]  D. Butterfield,et al.  The senescence-accelerated prone mouse (SAMP8): A model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease , 2005, Experimental Gerontology.

[23]  O. Alvarez-Garcia,et al.  Coexpression of MT1 and RORα1 melatonin receptors in the Syrian hamster Harderian gland , 2005, Journal of pineal research.

[24]  A. Coto-Montes,et al.  A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes , 2005, Journal of pineal research.

[25]  D. Swaab,et al.  The human pineal gland and melatonin in aging and Alzheimer's disease , 2005, Journal of pineal research.

[26]  C. Cotman,et al.  The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology , 2005, Journal of neuropathology and experimental neurology.

[27]  D. Selkoe,et al.  Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases , 2004, Nature Cell Biology.

[28]  D. Price,et al.  Stabilization of α-Synuclein Protein with Aging and Familial Parkinson's Disease-Linked A53T Mutation , 2004, The Journal of Neuroscience.

[29]  C. Ross,et al.  Protein aggregation and neurodegenerative disease , 2004, Nature Medicine.

[30]  J. Mariani,et al.  The “CholesteROR” Protective Pathway in the Vascular System , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  Jesus Avila,et al.  Role of tau protein in both physiological and pathological conditions. , 2004, Physiological reviews.

[32]  H. Chung,et al.  Alteration of soluble adhesion molecules during aging and their modulation by calorie restriction , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  G. Benítez-King,et al.  Melatonin prevents cytoskeletal alterations and oxidative stress induced by okadaic acid in n1e-115 cells , 2003, Experimental Neurology.

[34]  K. Davies,et al.  Proteasome inhibitors induce intracellular protein aggregation and cell death by an oxygen‐dependent mechanism , 2003, FEBS letters.

[35]  E. Haas,et al.  Alpha-synuclein: its biological function and role in neurodegenerative diseases. , 2003, Journal of molecular neuroscience : MN.

[36]  D. Mottet,et al.  Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. , 2002, Free radical biology & medicine.

[37]  Sang-Oh Yoon,et al.  Dose effect of oxidative stress on signal transduction in aging , 2002, Mechanisms of Ageing and Development.

[38]  J. Haddad Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. , 2002, Cellular signalling.

[39]  R. Hardeland,et al.  Effects of δ-aminolevulinic acid and melatonin in the harderian gland of female syrian hamsters , 2002 .

[40]  R. Hardeland,et al.  Melatonin protects against delta-aminolevulinic acid-induced oxidative damage in male Syrian hamster Harderian glands. , 2002, The international journal of biochemistry & cell biology.

[41]  K. Herrup,et al.  Progressive atrophy of cerebellar Purkinje cell dendrites during aging of the heterozygous staggerer mouse (Rora(+/sg)). , 2001, Brain research. Developmental brain research.

[42]  J. Mariani,et al.  The orphan nuclear receptor RORα is a negative regulator of the inflammatory response , 2001 .

[43]  Christian Haass,et al.  Subcellular Localization of Wild-Type and Parkinson's Disease-Associated Mutant α-Synuclein in Human and Transgenic Mouse Brain , 2000, The Journal of Neuroscience.

[44]  J. Ávila Tau aggregation into fibrillar polymers: taupathies , 2000, FEBS letters.

[45]  E. Stadtman,et al.  Protein Oxidation , 2000, Annals of the New York Academy of Sciences.

[46]  R. Hardeland,et al.  Antioxidative effects of melatonin in Drosophila melanogaster: Antagonization of damage induced by the inhibition of catalase , 1999, Journal of pineal research.

[47]  M. Festing,et al.  Genetic typing of the Senescence-Accelerated Mouse (SAM) strains with microsatellite markers , 1999, Mammalian Genome.

[48]  B. Hyman,et al.  Characterization of the Precursor Protein of the Non-Aβ Component of Senile Plaques (NACP) in the Human Central Nervous System , 1996, Journal of neuropathology and experimental neurology.

[49]  S. Reppert,et al.  Melatonin receptors step into the light: cloning and classification of subtypes. , 1996, Trends in pharmacological sciences.

[50]  B. Birren,et al.  Disruption of the nuclear hormone receptor RORα in staggerer mice , 1996, Nature.

[51]  D. Harman Role of Free Radicals in Aging and Disease , 1992, Annals of the New York Academy of Sciences.

[52]  Keiichi Higuchi,et al.  A new murine model of accelerated senescence , 1981, Mechanisms of Ageing and Development.

[53]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[54]  R. Sidman,et al.  Staggerer, a New Mutation in the Mouse Affecting the Cerebellum , 1962, Science.

[55]  M. Mattson,et al.  NF-kappa B as a therapeutic target in neurodegenerative diseases. , 2007, Expert opinion on therapeutic targets.

[56]  Zheng Feng,et al.  Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. , 2006, Free radical biology & medicine.

[57]  M. Aksenov,et al.  Cell culture models of oxidative stress and injury in the central nervous system. , 2005, Current neurovascular research.

[58]  J. Morley The SAMP8 mouse: a model of Alzheimer disease? , 2004, Biogerontology.

[59]  N. Weizman,et al.  Melatonin inhibits nuclear factor kappa B activation and oxidative stress and protects against thioacetamide induced liver damage in rats. , 2004, Journal of hepatology.

[60]  Shen-Liang Chen,et al.  Characterization of the Retinoid Orphan-Related Receptor-Coactivator Binding Interface : A Structural Basis for Ligand-Independent Transcription , 2002 .

[61]  R. Hardeland,et al.  Effects of delta-aminolevulinic acid and melatonin in the harderian gland of female Syrian hamsters. , 2002, Free radical biology & medicine.

[62]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[63]  J. Mariani,et al.  The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. , 2001, EMBO reports.

[64]  C. Carlberg,et al.  The potential role of the transcription factor RZR/ROR as a mediator of nuclear melatonin signaling. , 1998, Restorative neurology and neuroscience.

[65]  B. Birren,et al.  Disruption of the nuclear hormone receptor RORalpha in staggerer mice. , 1996, Nature.

[66]  E. Stadtman,et al.  Determination of carbonyl content in oxidatively modified proteins. , 1990, Methods in enzymology.